CION Ameerpet
A grade tells you how a brain tumour is likely to behave, not how far it has spread. Knowing what your WHO grade means is the first step to understanding your plan and your outlook.
When you are told you have a brain tumour, one of the first things the report will mention is a grade — a number from 1 to 4 set by the World Health Organization (WHO). The grade describes how the tumour is likely to behave: how quickly it grows and how aggressive its cells look under the microscope. Grade 1 is the slowest and least aggressive; Grade 4 is the fastest and most aggressive.
This matters because the grade — together with the tumour type and its molecular markers — guides how urgently treatment is needed, which treatments are used, and the likely outlook. On this page we explain each grade in plain language, why brain tumours are graded rather than staged, what a grade 4 brain tumour really means, and how markers such as the IDH mutation now change the grade. For the bigger picture of care, see our brain cancer and tumour hub.
Brain tumours are graded, not staged. Under the WHO Classification of Tumours of the Central Nervous System (5th edition, 2021), grade is now decided by combining how the cells look with molecular markers — so two tumours that look identical under the microscope can carry different grades. This is why the World Health Organization uses a Grade 1–4 scale for brain tumours rather than the Stage I–IV system used for most other cancers.
Most cancers are given a stage (I–IV) that describes how far the cancer has spread through the body. Brain tumours are given a grade (1–4) instead. The reason is simple: primary brain tumours — those that start in the brain — very rarely spread to other organs. So a spread-based staging system does not fit them.
Instead, the grade describes the behaviour of the tumour cells. If you have been told you have a "stage 4 brain tumour", it usually means one of two things: a Grade 4 primary tumour (most often glioblastoma), or that another cancer has spread to the brain (called brain metastases) — a very different situation. It is always worth clarifying which one your report describes.
| Stage (most cancers) | Grade (brain tumours) | |
|---|---|---|
| What it describes | How far the cancer has spread | How the tumour behaves and looks |
| Scale | Stage I to Stage IV | WHO Grade 1 to Grade 4 |
| Based on | Tumour size, lymph nodes, spread | Cell appearance + molecular markers |
| Why used | Most cancers spread through the body | Brain tumours rarely spread outside the CNS |
Each grade below describes how the tumour tends to behave and how it is usually managed. These are general patterns — your own plan always depends on the exact tumour type, its molecular markers, and your overall health.
Grade 1 tumours grow very slowly and their cells look close to normal under the microscope. They tend to have clear borders, which makes them easier to remove. Many Grade 1 tumours can be cured by surgery alone, and some may not need any further treatment. Examples include pilocytic astrocytoma (more common in children and young adults) and many meningiomas. Because they grow slowly, small Grade 1 tumours that are not causing symptoms are sometimes watched with regular MRI scans rather than treated immediately. Where surgery is needed, CION coordinates it with accredited neurosurgical partners, and delivers imaging, follow-up and supportive care directly.
Grade 2 tumours also grow slowly, but their cells look slightly more abnormal than Grade 1 and their borders are less distinct, so they can spread into nearby brain tissue. Examples include diffuse astrocytoma and oligodendroglioma. Many people with a Grade 2 glioma live well for years. The important point is that some Grade 2 tumours can change into a higher grade over time, which is why they are followed closely with MRI even after treatment. Treatment may be surgery, sometimes followed by radiation therapy, and molecular markers — especially the IDH mutation — strongly influence the plan and the outlook.
Grade 3 tumours are malignant (cancerous). Their cells look clearly abnormal and divide more quickly, and they invade surrounding brain tissue more actively than Grade 2. Examples include anaplastic astrocytoma and anaplastic oligodendroglioma. Treatment is usually more intensive — typically surgery followed by radiation therapy and chemotherapy. As with lower grades, molecular markers such as IDH mutation and 1p/19q co-deletion refine both the diagnosis and the treatment plan. CION delivers the radiation therapy (IMRT/IGRT) and systemic chemotherapy directly, coordinating any surgery with accredited neurosurgical partners.
Grade 4 is the most aggressive grade. The cells grow and divide rapidly and invade nearby brain tissue extensively. The most common Grade 4 tumour in adults is glioblastoma (GBM). A grade 4 diagnosis is serious and treated urgently — but it is not a fixed timeline, and outcomes vary widely between people. Treatment usually combines surgery, radiation therapy and chemotherapy. Molecular markers such as MGMT methylation help predict how well chemotherapy will work and guide the plan. We explain the outlook honestly, as ranges rather than guarantees, on our page about how tumour grade affects prognosis.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
Whether you have a Grade 1 tumour or a Grade 4 glioblastoma, our neuro-oncology team will explain what it means and the options — decisions for healing, not billing.
An MRI scan can suggest what a tumour is likely to be, but the grade is confirmed only after a sample of the tumour is examined. Here is how the process usually works.
An MRI with contrast shows the tumour's size, location and features that hint at how aggressive it may be. It is the starting point, but imaging alone cannot give a definitive grade.
A sample of the tumour is needed to confirm the diagnosis. This is taken either during surgery to remove the tumour, or as a targeted needle biopsy for tumours that are difficult to reach. Any surgery is carried out in coordination with accredited neurosurgical partners; CION arranges the pathology and molecular testing on the sample.
A pathologist examines the cells for features that indicate aggressiveness — how abnormal they look, how fast they are dividing, and whether there is dead tissue or abnormal blood vessels. Historically, this alone set the grade.
Since the 2021 WHO classification, molecular markers are combined with the microscope findings to reach the final grade and diagnosis. This is the single biggest change in how brain tumours are graded today — and the focus of the next section.
Ask a CION neuro-oncologist to walk you through your report — the consultation is free and there is no obligation to start treatment.
Before 2021, the grade was based almost entirely on how the tumour looked under the microscope. Today, the WHO combines that appearance with molecular markers — genetic features of the tumour cells. This matters because two tumours that look identical can behave very differently depending on their molecular profile. The most important markers include:
A practical consequence: a tumour that "looks" like a lower grade under the microscope may be classified as a higher grade because its molecular markers show it will behave more aggressively. This is why CION arranges molecular testing on the biopsy sample as standard for malignant gliomas — a grade set without these markers may be incomplete.
According to the European Association of Neuro-Oncology (EANO) and NCCN guidelines, molecular testing at diagnosis is now considered essential for gliomas — not optional. If your report gives a grade but does not mention markers such as IDH or MGMT, it is reasonable to ask whether molecular testing has been done. A second opinion is a good moment to check.
The grade is one of the main factors guiding treatment. The table below is a general guide — every plan is set individually by CION's tumour board.
| Grade | General behaviour | Typical treatment approach |
|---|---|---|
| Grade 1 | Very slow-growing; often curable | Surgery alone; sometimes watch-and-wait with MRI |
| Grade 2 | Slow-growing; can change over years | Surgery, sometimes followed by radiation; close MRI follow-up |
| Grade 3 | Moderately aggressive | Surgery + radiation therapy + chemotherapy |
| Grade 4 | Highly aggressive (e.g. glioblastoma) | Urgent surgery + radiation + chemotherapy together |
CION delivers radiation therapy (IMRT/IGRT), chemotherapy, imaging, molecular testing and supportive care directly, and coordinates any neurosurgery with accredited neurosurgical partners. For the full pathway, see our brain tumour treatment in Hyderabad page.
The grade drives so much of the plan that it is worth being confident it is complete. A free second opinion is particularly useful when:
Remember that the grade is only one factor in your outlook — tumour type, molecular markers, your age and health, and how much tumour can be safely removed all matter too. Published survival figures from NCCN, EANO and SEER are given as ranges, never guarantees. We explain this sensitively on our page about how tumour grade affects prognosis.
Call 18002028726 or request a free callback to have your grade explained by CION's neuro-oncology team.
Get a free written second opinion from CION's neuro-oncology tumour board — particularly valuable if molecular testing (IDH, MGMT, 1p/19q) has not been arranged for your report.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.The WHO grade describes how a brain tumour is likely to behave — how fast it grows and how aggressive its cells look under the microscope. It runs from Grade 1 (slowest, least aggressive) to Grade 4 (fastest, most aggressive). Brain tumours are graded, not staged, because they very rarely spread outside the brain and spinal cord. The grade is one of the strongest guides to how urgently treatment is needed, which treatments are used, and the likely outlook. Since the 2021 WHO classification, the grade is decided together with molecular markers such as the IDH mutation, not by the microscope alone.
No. Most cancers are given a stage (I–IV) that describes how far the cancer has spread through the body. Brain tumours are given a grade (1–4) instead, because primary brain tumours almost never spread to other organs. The grade describes the tumour cells' behaviour, not their spread. This is why you will see "Grade 4 glioblastoma" rather than "Stage 4 brain cancer". If you have been told you have a "stage 4 brain tumour", it usually means either a Grade 4 primary tumour or that another cancer has spread to the brain — two very different situations worth clarifying with your oncologist.
A Grade 4 brain tumour is the most aggressive grade — the cells grow and divide rapidly and invade nearby brain tissue. The most common Grade 4 tumour in adults is glioblastoma (GBM). A Grade 4 diagnosis is serious, but it is not a fixed timeline. Outcomes vary with age, general health, how much tumour is safely removed, and molecular markers such as MGMT methylation. Treatment usually combines surgery (coordinated with accredited neurosurgical partners), radiation therapy, and chemotherapy. Grade 4 tumours are treated urgently — but the exact plan, and what to expect, is highly individual.
Yes — some lower-grade gliomas (Grade 2 and 3) can change over the years into a higher grade, a process called transformation or progression. This is why even a slow-growing Grade 2 tumour is followed with regular MRI scans rather than ignored. If a scan or new symptoms suggest the tumour is changing, a repeat biopsy may be needed to confirm the new grade before adjusting treatment. Molecular markers, particularly IDH status, help predict how likely a tumour is to transform. According to NCCN and EANO guidance, molecular testing at diagnosis is central to setting the right monitoring schedule.
Since the 2021 WHO classification, a brain tumour's grade is decided by combining how the cells look with their molecular markers — not by the microscope alone. For example, the IDH mutation separates gliomas into groups with very different behaviour, and certain genetic changes can move a tumour that "looks" lower grade into a higher grade because it will behave more aggressively. This means two tumours that look identical under the microscope can now carry different grades and different treatment plans. It is why CION arranges molecular testing on the biopsy sample as standard for malignant gliomas.
The grade is one of the most important factors, but it is not the whole picture. Published survival figures from NCCN, EANO and SEER are given as ranges, and your own outlook depends on the tumour type, its molecular markers (IDH, MGMT, 1p/19q), your age and general health, and how much tumour can be safely removed. Two people with the same grade can have very different journeys. We explain this in plain language on our page about how tumour grade affects prognosis. If you want your specific report explained, a CION neuro-oncology second opinion is free.
As a general guide: Grade 1 tumours are often managed with surgery alone and may be curable. Grade 2 tumours are treated with surgery, sometimes followed by radiation, and slow-growing ones may be watched with regular MRI. Grade 3 tumours usually need surgery plus radiation and chemotherapy. Grade 4 tumours (glioblastoma) are treated urgently with surgery, radiation and chemotherapy together. CION delivers radiation therapy, chemotherapy, imaging, molecular testing and supportive care directly, and coordinates any neurosurgery with accredited neurosurgical partners. Every plan is set by a tumour board — see our brain tumour treatment page.
Browse our complete guide to brain tumours and brain cancer — symptoms, scans, tumour types, treatment, prognosis and life after treatment. Tap any topic to read more.